Orthobiologics

CURASAN entered the U.S. market with the first U.S. implantation of CERASORB® Ortho Foam bone graft....

Carmell Therapeutics will launch a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material product/indication, designed to treat fractures....

Histogenics successfully completed consultations with Japan’s PMDA regarding the regulatory path for NeoCart® autologous cell therapy for the treatment of knee cartilage...

TheraCell was issued U.S. Patent No. 9,636,436, "Compositions of and Methods for Cancellous Bone Matrix," addressing its ECS™ enhanced cancellous demineralized...

SpinalCyte was issued Australian Patent No. 2013299505, “Generation of Cartilage Ex Vivo from Fibroblasts.”...

CellRight Technologies launched Matrix OI® Cortical Fibers, the latest in vivo verified osteoinductive matrix in its portfolio of regenerative human-derived...

Orthocell received a new patent in Singapore titled "Method for Producing a Collagen Membrane and Uses Thereof," relative to the CelGro®...

Six-month results from Phase I/II study indicate that RepliCel’s RCT-01 fibroblasts demonstrated product safety and clinical potential for tendon regeneration...

Burst Biologics received IRB approval for a U.S. prospective clinical study of BioBurst cellular allograft in spinal fusion....

Study results indicate that Rotation Medical’s collagen-based Bioinductive Implant induced new tissue formation in all study participants with large and massive...